Ru-Rong Ji Selected Research

Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)

10/2013	Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons.
10/2010	Light touch induces ERK activation in superficial dorsal horn neurons after inflammation: involvement of spinal astrocytes and JNK signaling in touch-evoked central sensitization and mechanical allodynia.
4/2009	JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain.
3/2009	Activation of extracellular signal-regulated kinase in the anterior cingulate cortex contributes to the induction and expression of affective pain.
4/2008	Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity.
2/2006	Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats.
3/2005	ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model.
1/2002	ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ru-Rong Ji Research Topics

Disease

96	Pain (Aches) 01/2022 - 01/2002
58	Hyperalgesia 01/2021 - 09/2002
55	Neuralgia (Stump Neuralgia) 10/2021 - 04/2002
26	Inflammation (Inflammations) 01/2021 - 01/2002
26	Hypersensitivity (Allergy) 12/2020 - 01/2002
24	Chronic Pain 01/2020 - 07/2009
18	Neoplasms (Cancer) 10/2021 - 05/2008
11	Neuroinflammatory Diseases 01/2021 - 07/2009
7	Postoperative Pain 10/2021 - 01/2009
6	Cancer Pain 01/2021 - 09/2009
5	Peripheral Nerve Injuries 01/2017 - 09/2003
4	Pruritus (Itching) 01/2021 - 11/2010
4	Edema (Dropsy) 01/2021 - 07/2006
4	Bone Neoplasms (Bone Cancer) 01/2021 - 05/2015
4	Acute Pain 12/2020 - 12/2011
3	Arthritis (Polyarthritis) 01/2021 - 09/2011
3	Infections 01/2021 - 01/2019
3	Diabetic Neuropathies (Diabetic Neuropathy) 01/2019 - 08/2011
2	Allergic Contact Dermatitis 01/2021 - 04/2016
2	Bites and Stings (Sting) 01/2021 - 01/2021
2	Lymphoma (Lymphomas) 01/2020 - 01/2018
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2019 - 01/2019
2	Neoplasm Metastasis (Metastasis) 01/2019 - 04/2010
2	Gliosis 04/2016 - 11/2012

Drug/Important Bio-Agent (IBA)

24	CytokinesIBA 01/2021 - 07/2006
15	Opioid Analgesics (Opioids)IBA 10/2021 - 09/2002
13	ChemokinesIBA 12/2020 - 07/2009
13	Formaldehyde (Formol)FDA Link 01/2020 - 03/2006
13	Analgesics (Analgesic Drugs)IBA 01/2019 - 09/2002
12	Capsaicin (Zostrix)FDA Link 01/2021 - 09/2004
11	LipidsIBA 12/2020 - 05/2010
10	p38 Mitogen-Activated Protein KinasesIBA 01/2018 - 09/2002
9	Morphine (MS Contin)FDA LinkGeneric 01/2021 - 09/2002
9	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2016 - 09/2002
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2014 - 07/2006
9	Mitogen-Activated Protein KinasesIBA 12/2013 - 01/2002
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 11/2016
8	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2013 - 01/2002
7	Ion Channels (Ion Channel)IBA 12/2021 - 09/2002
7	Peptides (Polypeptides)IBA 01/2018 - 03/2006
7	Proteins (Proteins, Gene)FDA Link 10/2017 - 09/2002
7	Freund's AdjuvantIBA 01/2016 - 01/2002
6	Monoclonal AntibodiesIBA 08/2021 - 01/2014
6	protectin D1IBA 01/2021 - 10/2011
6	Neurotransmitter Agents (Neurotransmitter)IBA 12/2018 - 08/2005
6	D-JNKI-1IBA 02/2018 - 03/2006
6	Phosphotransferases (Kinase)IBA 01/2018 - 09/2004
6	Neutralizing AntibodiesIBA 09/2016 - 07/2007
6	Small Interfering RNA (siRNA)IBA 02/2016 - 11/2010
6	JNK Mitogen-Activated Protein KinasesIBA 11/2010 - 03/2006
5	resolvin D1IBA 01/2021 - 09/2011
5	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2020 - 04/2012
5	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 12/2013
5	Interleukin-1beta (Interleukin 1 beta)IBA 03/2012 - 07/2006
4	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 03/2008
4	Voltage-Gated Sodium ChannelsIBA 02/2018 - 04/2002
4	Messenger RNA (mRNA)IBA 04/2016 - 09/2002
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2016 - 09/2004
4	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 11/2014 - 09/2003
4	Glutamic Acid (Glutamate)FDA Link 12/2013 - 09/2002
4	5S,12R,18R- trihydroxy- 6Z,8E,10E,14Z,16E- eicosapentaenoic acidIBA 03/2013 - 05/2010
4	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 12/2011 - 05/2010
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2020 - 08/2007
3	Pharmaceutical PreparationsIBA 12/2020 - 06/2011
3	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2020 - 09/2005
3	NeuropeptidesIBA 01/2019 - 10/2007
3	Minocycline (Cyclops)FDA LinkGeneric 02/2018 - 11/2012
3	Docosahexaenoic AcidsIBA 01/2018 - 11/2011
3	InterleukinsIBA 01/2017 - 10/2010
3	Interleukin-6 (Interleukin 6)IBA 01/2017 - 05/2008
3	N-Methylaspartate (NMDA)IBA 01/2016 - 08/2005
3	TRPV Cation ChannelsIBA 10/2007 - 09/2004
2	Programmed Cell Death 1 ReceptorIBA 08/2021 - 07/2017
2	InterferonsIBA 01/2021 - 01/2021
2	Interferon Type IIBA 01/2021 - 01/2021
2	Interleukin-23 (Interleukin 23)IBA 01/2021 - 01/2021
2	NivolumabIBA 01/2021 - 01/2020
2	Ala(2)-MePhe(4)-Gly(5)- Enkephalin (DAGO)IBA 01/2021 - 09/2005
2	LipopolysaccharidesIBA 01/2021 - 01/2018
2	Cytostatic AgentsIBA 12/2020 - 11/2016
2	Histamine (Histamine Dihydrochloride)FDA Link 01/2020 - 11/2010
2	MicroRNAs (MicroRNA)IBA 01/2020 - 04/2014
2	GTP-Binding Proteins (G-Protein)IBA 10/2019 - 05/2014
2	Toll-Like Receptor 4IBA 01/2019 - 04/2016
2	U 0126 (UO 126)IBA 02/2018 - 01/2002
2	Protein Isoforms (Isoforms)IBA 01/2018 - 11/2016
2	7,14- dihydroxydocosa- 4,8,10,12,16,19- hexaenoic acidIBA 01/2018 - 04/2012
2	Therapeutic UsesIBA 01/2018 - 09/2003
2	Caspase 6IBA 01/2017 - 03/2014
2	Sodium Channels (Sodium Channel)IBA 01/2016 - 12/2015
2	Adenosine Triphosphate (ATP)IBA 05/2015 - 12/2013

Therapy/Procedure

29	Spinal Injections 01/2021 - 01/2002
18	Therapeutics 01/2021 - 09/2002
13	Ligation 02/2016 - 05/2003
10	Drug Therapy (Chemotherapy) 01/2021 - 04/2012
8	Analgesia 10/2020 - 03/2012
3	Immunotherapy 08/2021 - 01/2020
3	Spinal Cord Stimulation 01/2021 - 07/2015
2	Immunomodulation 08/2021 - 01/2020
2	Injections 04/2016 - 09/2009